Max Healthcare Institute Gears Up for Q3 Reveal on 5th February; Check Key Expectations Here

Posted by : sachet | Wed Feb 04 2026

Click and Sign Up to Get Live Updates on Q3 Results

Max Healthcare Institute’s Q3 results for FY26 are scheduled to be announced on 5th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Max Healthcare Institute Q3 Results 2026 Preview

Max Healthcare Institute’s revenue is expected to be in the range of ₹1,868.31 crore, a 9.42% YoY increase.
Profit After Tax, or PAT, is projected to fall 15.26% YoY.
Net profit is ₹238.80 crore, up 15.26% YoY
EBITDA to fall 10.49%

Max Healthcare Institute Share Performance

Over the past six months, Max Healthcare Institute’s share price has fallen by 18.23% to ₹227.90.
Moreover, over the past year, the stock has decreased by 12.93%.
Despite this weak short-term performance, Max Healthcare Institute’s stock has delivered a financially sound 470.59% return over the past 5 years.
As of 4th February 2026, the stock traded at ₹1,022.50 per share.

Key Factors to Watch for Max Healthcare Institute Q3 Results FY26

Revenue & Patient Volume: Track growth in total revenue and patient volumes, including occupied bed days.
ARPOB & Margins: Monitor average revenue per occupied bed and EBITDA/net profit margins.
Bed Occupancy & Specialty Mix: Assess occupancy rates and contribution from specialty departments.
International Patients & New Facilities: Watch inflows from medical tourism and performance of newly operational hospitals.
Management Outlook: Focus on expansion plans, cost management, and balance sheet health.

Final Thoughts

Max Healthcare Institute will announce its Q3 FY26 results on 5th February 2026. Analysts expect a 9.42% revenue growth, a 15.26% fall in PAT, and a 10.49% decline in EBITDA. Max Healthcare’s Q3 FY26 results, focus on revenue and patient volumes, ARPOB and margins, bed occupancy and specialty mix, international patient inflows, and management guidance on expansion and costs.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!